Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: 9926.HKEX
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Akeso (9926) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

BUY

HK$105

+16.0%

2031

5-Year

BUY

HK$179

+97.6%

Published batch insight

Bispecific Clinical Superiority Meets Unforgiving Western Valuation Realities

A dense consensus reveals sharp divergence between undeniable clinical survival data and aggressive equity valuations. While domestic reimbursement volume drives self-funding commercial scale, long-duration multiples face severe headwinds from partner royalty limitations, multinational bispecific competition, and restrictive sovereign discount rates.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Warren Buffett (Value Purist), Sherlock Holmes (Whistleblower), Universal Investor (Polymath), Superintelligence (Anthropologist), Elon Musk (Visionary), Machiavelli (Insider), J.P. Morgan (Titan), Ray Dalio (Strategist), Michael Burry (Vulture). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Akeso at the forecast anchor (2026-09-18): $19,889 in five years versus $13,892 for S&P 500 benchmark.

Akeso · Synthesized ConsensusS&P 500 benchmark

Figure: Five-year synthesized consensus value path for Akeso compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in HKD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 90.5 HKD1-year price return: +16.04%5-year price return: +97.57%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in HKD, with returns and rationale
Quarter	Target (HKD)	Quarter return	Total return	Forecast rationale
Q4 2026	94.50	+4.42%	+4.42%	Regulatory scrutiny surrounding initial Western filings creates volatility, but expanding fourth-quarter domestic hospital shipments under comprehensive national reimbursement listings cushion overall sentiment and reinforce baseline operational progress.
Q1 2027	97.55	+3.23%	+7.79%	Full-year results confirm commercial sales growth exceeding twenty-five percent and narrowing operational losses, though elevated global discount rates and trial cash burn cap speculative valuation multiple expansion.
Q2 2027	101.99	+4.55%	+12.70%	Oncology congress disclosures highlight robust survival data across secondary solid tumor indications, prompting tactical accumulation while investors await definitive multiregional clinical trial updates from overseas partners.
Q3 2027	105.02	+2.97%	+16.04%	Interim financial reporting confirms steady hospital volume ramp, but tightening monetary conditions and digestion of foreign clinical data prompt moderate profit-taking across long-duration healthcare holdings.
Q4 2027	110.16	+4.89%	+21.72%	Domestic reimbursement renewal adjustments impose expected price concessions on earlier indications, yet overall prescription elasticity and early milestone receipts preserve top-line momentum and stabilize gross profit generation.
Q1 2028	113.79	+3.30%	+25.74%	Annual disclosures indicate the domestic business is approaching cash-flow breakeven as manufacturing economies of scale dilute fixed costs, reducing perceived balance sheet vulnerability among institutional allocators.
Q2 2028	119.66	+5.16%	+32.22%	Pivotal multiregional Phase III survival data readouts demonstrate solid efficacy in broader patient cohorts, partially de-risking Western commercialization and triggering contractually guaranteed partner milestone inflows.
Q3 2028	124.22	+3.81%	+37.26%	Global regulatory filings advance smoothly, but competitive clinical updates from multinational pharmaceutical fast-followers temper long-term terminal pricing assumptions and induce disciplined equity price consolidation.
Q4 2028	131.33	+5.72%	+45.11%	Western regulatory progress triggers initial licensing milestone revenues, while domestic label expansions across gastrointestinal cancers widen patient volume, supporting fundamental valuation progression into fiscal year-end.
Q1 2029	136.07	+3.61%	+50.35%	Audited results confirm inaugural corporate operating breakeven, marking a pivotal transition from developmental cash burn toward self-funding commercial viability across core Asian oncology franchises.
Q2 2029	139.85	+2.78%	+54.53%	Commercial preparation for Western product rollouts progresses, alongside advancing clinical trials for next-generation bispecific antibody-drug conjugates that replenish the firm's long-term organic development pipeline.
Q3 2029	144.05	+3.00%	+59.17%	Initial Western commercial shipments begin yielding recurring low-double-digit royalty flows, which provide pure-margin cash accretion that counters ongoing clinical research expenditures.
Q4 2029	150.07	+4.18%	+65.82%	Routine reimbursement renegotiations in China moderate unit realizations, but high hospital penetration and expanding patient cohorts maintain consolidated revenue compounding and preserve operating profitability.
Q1 2030	154.94	+3.25%	+71.21%	Annual financial reporting demonstrates positive net earnings and expanding free cash flow, encouraging long-only institutional accumulation as multiple discovery shifts toward price-to-earnings metrics.
Q2 2030	160.37	+3.50%	+77.20%	Secondary indication approvals in major international jurisdictions broaden the global addressable patient population, supporting royalty remittance compounding despite encroaching biosimilar competition.
Q3 2030	161.25	+0.55%	+78.18%	Maturing oncology indications experience modest market share stabilization, prompting brief valuation consolidation while the market evaluates clinical trial progress in non-oncology autoimmune pipelines.
Q4 2030	166.25	+3.10%	+83.70%	Sustained global royalty collections and disciplined factory capacity utilization deliver consistent cash generation, prompting management to evaluate initial shareholder capital return frameworks.
Q1 2031	170.72	+2.69%	+88.64%	Full-year reporting validates durable double-digit operating margins, confirming that high-margin overseas royalties successfully complement high-volume domestic sales to sustain institutional earnings quality.
Q2 2031	174.72	+2.34%	+93.06%	Next-generation antibody-drug conjugates enter late-stage registrational studies, sustaining platform innovation premiums while established bispecific franchises generate predictable recurring commercial cash flows.
Q3 2031	178.80	+2.34%	+97.57%	The five-year scenario concludes with the business firmly established as an integrated, cash-generative biopharmaceutical enterprise trading at a normalized through-cycle earnings valuation.

The investment thesis hinges on separating Akeso's verified domestic commercial inflection from the speculative capitalization of its overseas royalty rights. Domestically, twelve indications listed on the National Reimbursement Drug List drive commercial sales growth near thirty percent, successfully absorbing fixed clinical infrastructure and narrowing operating deficits toward breakeven. However, market pricing frequently conflates Summit Therapeutics' prospective gross product revenues with Akeso's contractual low-double-digit royalty entitlement. Against five-percent sovereign benchmark yields and strict foreign regulatory scrutiny, the firm's rich price-to-sales multiple faces persistent gravitational drag, requiring realized operational cash flows rather than clinical narratives to support valuation.

Key insights

Contractual licensing structures cap Akeso's foreign economic capture at modest royalties, shifting execution burdens to partners while restricting unencumbered equity upside.
Reimbursement-driven domestic volume growth overcomes statutory price discounts, establishing a self-sustaining operational baseline independent of Western regulatory timing or geopolitical frictions.
Competing multiregional bispecific and antibody-drug conjugate pipelines from well-capitalized multinational pharmaceutical peers threaten to compress the first-mover commercial exclusivity window.

Deep Dive

The prevailing consensus treats ivonescimab's survival victory over standard checkpoint inhibitors as a guaranteed global blockbuster annuity, pricing frictionless Western commercialization. Sell-side analysts anchor heavily on aggressive peak sales projections, assuming regulatory agencies will rapidly clear Chinese-origin clinical data while largely ignoring domestic reimbursement price renegotiations and persistent operational cash burn.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd underestimates the standalone profitability of Akeso's domestic commercial engine while overestimating near-term Western cash velocity. The critical analytical edge lies in recognizing that Akeso captures only a low-double-digit royalty on overseas sales, not gross revenues. However, twelve domestic reimbursement listings provide an underappreciated, self-funding commercial fortress that insulates corporate solvency even if foreign regulatory milestones face delays.

Repricing catalyst

The primary convergence catalyst is the sequence of global Phase III multiregional clinical trial readouts, alongside upcoming Western regulatory filing reviews. Statistically robust survival confirmation across non-Asian patient cohorts will force institutional allocators to replace speculative pipeline multiples with tangible forward royalty cash-flow models, narrowing the equity risk premium.

Published consensus context

Macro regime alignment

The prevailing macroeconomic regime of restrictive central bank interest rates and elevated sovereign yields represents a persistent valuation headwind for long-duration biotechnology assets. This setup enforces multiple compression on speculative earnings, although Akeso's liquid reserves exceeding nine billion renminbi completely insulate its clinical pipeline from debt refinancing distress.

Published consensus context

Advisor disagreement

The decisive disagreement centers on whether Akeso's valuation should reflect an emerging global pharmaceutical titan or a domestic commercial innovator. Optimistic models assume seamless Western regulatory approvals, projecting multi-billion-dollar royalty windfalls that justify premium sales multiples. Contrarian perspectives emphasize that Akeso captured only a royalty slice rather than gross Western revenues, while highlighting interim trial variance, aggressive Chinese reimbursement price cuts, and the valuation drag of elevated discount rates. Reconciling this debate requires observing whether multiregional survival trials replicate domestic efficacy and whether domestic volume expansion delivers positive operating cash flow by 2028.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Reimbursement volume accelerates domestic adoption: Integration of twelve core indications across five commercial products into China's National Reimbursement Drug List unlocks rapid hospital penetration. Expanding prescription volumes across thoracic and gynecological oncology compensate for negotiated unit price concessions, delivering sustained product sales growth above twenty-five percent and systematically absorbing manufacturing overhead. Expected impact: +36%.
Partner licensing generates high-margin royalties: The out-licensing agreement with Summit Therapeutics externalizes the substantial capital expenditure of multiregional Western trials. Impending regulatory milestones and low-double-digit royalties on ex-China commercial sales provide zero-marginal-cost cash inflows that drop directly to net operating income, accelerating corporate progression toward cash self-sufficiency. Expected impact: +28%.
Proven clinical survival superiority moat: Head-to-head clinical trials establishing statistically significant progression-free and overall survival advantages over standard-of-care monotherapies dismantle conventional oncology regimens. Therapeutic differentiation in first-line lung and gastrointestinal cancers secures physician prescribing loyalty, defending premium formulary positioning and expanding the long-term addressable patient population. Expected impact: +24%.
Biomanufacturing scale expands operating leverage: In-house large-scale biomanufacturing facilities in southern China generate substantial unit cost advantages over outsourced models. As commercial production scales, fixed operating expenses amortize over expanding volume, defending gross margins near eighty percent and driving corporate operating margins across the breakeven threshold into sustainable profitability. Expected impact: +18%.

Top frictions and headwinds

Monetary tightening compresses long-duration multiples: Persistent central bank policy tightening and benchmark sovereign yields near five percent elevate corporate capital costs. Higher discount rates severely penalize long-duration biotechnology valuation multiples, forcing equity pricing to anchor strictly on realized operating cash flows rather than distant projected pipeline royalty streams. Expected impact: -20%.
National reimbursement mandatory price clawbacks: Periodic centralized procurement renegotiations by China's National Healthcare Security Administration enforce recurring price concessions on mature indications. These administrative price reductions cap unit revenue realizations, requiring continuous volume expansion across hospital networks simply to preserve baseline gross profit contributions over time. Expected impact: -16%.
Fast-follower bispecific and ADC crowding: Global pharmaceutical giants and agile domestic biopharma competitors are rapidly mobilizing competing dual-targeting antibodies and antibody-drug conjugate regimens. This encroaching competitive pipeline threatens to shorten Akeso's clinical exclusivity window, compress terminal market share, and escalate detailing expenditures in crowded frontline oncology indications. Expected impact: -14%.
Persistent multiregional clinical trial burn: Sustaining dozens of concurrent global and domestic registrational clinical trials consumes substantial research capital, exceeding CNY 1.5 billion annually. Heavy clinical trial expenditures maintain headline operating losses and defer corporate free cash flow inflection until commercial revenues achieve critical mass. Expected impact: -12%.

Tail risks

Multiregional trial survival replication failure: Pivotal multiregional Phase III trials could fail to replicate China's remarkable survival superiority in Western demographic cohorts due to biological variance or standard-of-care differences. This event carries a thirty-one percent probability and would dismantle foreign licensing expectations, triggering severe multiple compression and stranding the firm within domestic markets. Probability: +31%. Expected impact: -42%.
Geopolitical biosecurity cross-border licensing sanctions: Escalating cross-border geopolitical friction could culminate in targeted legislative measures restricting biotechnology collaboration or royalty repatriations from Chinese clinical intellectual property. Carrying a twenty-two percent probability, this risk would disrupt Western distribution channels, halt overseas clinical operations, and impose a permanent geopolitical risk discount on the equity. Probability: +22%. Expected impact: -38%.

Tail opportunities

Accelerated Western regulatory approval milestone: Foreign regulatory agencies could grant priority review or accelerated approval for ivonescimab based on mature multiregional clinical subsets. This outcome carries a thirty-two percent probability due to strict foreign trial scrutiny, but it would pull forward hundreds of millions in development milestones and activate lucrative Western royalties years ahead of schedule. Probability: +32%. Expected impact: +45%.
Multinational licensing of secondary pipeline: A tier-one global pharmaceutical company facing patent-cliff exposure could acquire exclusive international rights to Akeso's bispecific antibody-drug conjugate or autoimmune candidates. Triggered by breakthrough Phase II solid tumor data, a major deal carries a twenty-four percent probability and would deliver substantial upfront cash, permanently removing external financing risks. Probability: +24%. Expected impact: +38%.

What to monitor

Thesis watchpoints

Three decisive observations will validate or challenge the investment thesis over the forecast horizon:

Key insights

Confirmation: Domestic product sales exceeding RMB 4.0 billion annualized while semi-annual operating losses narrow below CNY 300 million through late 2027.
Deterioration: Multiregional Phase III progression-free survival hazard ratios degrading above 0.70 or foreign regulators requiring new standalone Western clinical trials.
Reassessment: Gross profit margins declining below 72% following national reimbursement renewals, or liquid cash reserves breaching beneath RMB 6.0 billion before breakeven.

Company Financial Analysis

Akeso Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Akeso's financial performance highlights a company rapidly transitioning from heavy clinical spending to commercial self-sufficiency. Commercial drug sales expanded 51.5% in fiscal 2025 to RMB 3.03 billion, with momentum continuing into the first half of 2026 as product revenue rose 28.7% to RMB 1.80 billion. Net operating losses contracted from RMB 918 million in 2025 to RMB 418 million in interim 2026, confirming that rising prescription sales are beginning to outrun baseline overhead costs. This trend demonstrates that hospital prescription demand is driving the business rather than one-time licensing fees. As manufacturing scale improves and overseas royalties begin flowing in, fixed expenses will be diluted further, paving a realistic path toward full operational profitability.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	CNY 3B	CNY -1.1B	CNY -1.8B
2024	HKD 2.1B	HKD -514.5M	HKD -1.1B
2023	HKD 4.5B	HKD 2B	CNY 1.6B
2022	CNY 837.7M	CNY -1.2B	CNY -2B
2021	CNY 225.6M	CNY -1.1B	CNY -1.7B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	--	TTM	Loss-making	HKD / --
2024	30.6x	TTM	USD-normalized	HKD / --
2023	--	TTM	Unavailable	HKD / --
2022	--	Annual	Loss-making	HKD / CNY
2021	--	Annual	Loss-making	HKD / CNY

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Akeso's margins reveal strong underlying manufacturing economics alongside classic biotechnology growth dynamics. Gross profit margins printed at a robust 78.7% in 2025, supported by proprietary biologic production efficiencies despite government reimbursement price discounts. Operating margins remained negative at -30.8% due to active research trials, but narrowed dramatically from negative 160% in 2022. This steady improvement demonstrates powerful operating leverage overcoming statutory price cuts. Because future overseas royalty payments carry virtually zero manufacturing costs, high gross margins will directly lift the bottom line as global sales materialize, driving sustained profit margin expansion.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	CNY -918.2M	-30.8%	-36.4%
2024	HKD -570.4M	-26.9%	-24.2%
2023	HKD 2B	45.2%	44.8%
2022	CNY -1.3B	-160.0%	-139.5%
2021	CNY -1.2B	-553.0%	-476.4%

Balance sheet and leverage

AI Review

Akeso maintains exceptional financial strength that insulates the business from credit market volatility. As of mid-2026, liquid cash and short-term financial assets stood at RMB 9.16 billion, substantially exceeding total obligations. A conservative debt-to-equity ratio of 0.50 and a current ratio of 5.14 demonstrate that short-term solvency risk is essentially nonexistent. This large cash cushion gives management strategic independence, providing multiple years of operational runway without the need for dilutive share sales or expensive debt. It ensures that planned clinical pipelines can be funded internally while commercial sales scale toward self-sufficiency.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	CNY 4.6B	CNY 9.2B	CNY 4.3B net cash	5.14x
2024	CNY 4B	CNY 7.3B	CNY 2.9B net cash	5.15x
2023	CNY 3B	CNY 4.9B	CNY 1.1B net cash	4.71x
2022	CNY 1.9B	CNY 2.3B	CNY 213.3M net cash	2.25x
2021	CNY 859.4M	CNY 2.6B	CNY 1.8B net cash	4.81x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management's spending shows disciplined capital allocation following an aggressive phase of factory construction. Capital expenditures dropped from over ninety percent of revenue in 2022 to 23.9% in 2025 as major manufacturing facilities were completed. Meanwhile, research and development spending remained focused at CNY 1.53 billion in 2025 and CNY 773 million in the first half of 2026, advancing core late-stage clinical programs. This shift from physical construction to clinical development preserves capital while ensuring ample factory capacity to supply expanding hospital sales. By partnering with external developers to fund expensive Western trials, Akeso protects its cash reserves while maintaining high-margin participation in global drug sales.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	CNY 712.1M	CNY 1.5B
2024	HKD 585.8M	HKD 1.2B
2023	CNY 879.5M	HKD 1.3B
2022	CNY 775.6M	CNY 1.3B
2021	CNY 712.1M	CNY 1.1B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	NEUTRAL	127	+19%	Not available	ORIGINAL
5Y	BUY	164	+131%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	86.88	94.7	103.17	14
+6M	March 18, 2027	82.54	98.88	111.42	14
+9M	June 18, 2027	84.19	104.64	124.79	14
+1Y	September 18, 2027	81.66	107.69	142.09	14
+15M	December 18, 2027	82.48	114.72	161.98	14
+18M	March 18, 2028	85.78	120.03	168.46	14
+21M	June 18, 2028	91.78	127.56	183.62	14
+2Y	September 18, 2028	95.61	131.71	205.66	14
+27M	December 18, 2028	99.26	141.58	236.51	14
+30M	March 18, 2029	101.42	149.53	262.52	14
+33M	June 18, 2029	104.46	156.39	280.9	14
+3Y	September 18, 2029	102.37	160.62	303.37	14
+39M	December 18, 2029	106.47	168.54	321.57	14
+42M	March 18, 2030	108.6	176.44	347.3	14
+45M	June 18, 2030	111.85	183.07	357.72	14
+4Y	September 18, 2030	112.97	185.09	382.76	14
+51M	December 18, 2030	116.36	191.93	398.07	14
+54M	March 18, 2031	118.69	198.87	417.97	14
+57M	June 18, 2031	119.88	204.17	434.69	14
+5Y	September 18, 2031	122.27	209.06	447.73	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Frozen comparison context

USDHKD.FOREX forecast context

The batch's original inverse_usd_to_listing path is preserved for transparent interpretation of USD-normalized returns.

FX snapshot: 7.85 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	7.7715	7.8388	7.85
+6M	March 18, 2027	7.7715	7.8051	7.85
+9M	June 18, 2027	7.7715	7.7827	7.85
+1Y	September 18, 2027	7.7715	7.7993	7.85
+15M	December 18, 2027	7.7715	7.816	7.85
+18M	March 18, 2028	7.6938	7.8215	7.85
+21M	June 18, 2028	7.7707	7.8213	7.85
+2Y	September 18, 2028	7.7707	7.8212	7.85
+27M	December 18, 2028	7.7707	7.8155	7.85
+30M	March 18, 2029	7.7707	7.8099	7.85
+33M	June 18, 2029	7.693	7.793	7.85
+3Y	September 18, 2029	7.7699	7.8041	7.85
+39M	December 18, 2029	7.7699	7.8096	7.85
+42M	March 18, 2030	7.7699	7.8151	7.85
+45M	June 18, 2030	7.7699	7.815	7.85
+4Y	September 18, 2030	7.7692	7.7982	7.85
+51M	December 18, 2030	7.693	7.7981	7.85
+54M	March 18, 2031	7.693	7.7981	7.85
+57M	June 18, 2031	7.693	7.7981	7.85
+5Y	September 18, 2031	7.693	7.7981	7.85

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The consensus centers on an independently supported operational reality: commercial domestic revenues are rapidly expanding across twelve reimbursed oncology indications, narrowing operating losses while backed by a solid liquid cushion of over nine billion renminbi. However, substantial divergence emerges concerning the valuation of offshore assets. Highly weighted reports rigorously document that Western rights were out-licensed for low-double-digit royalties rather than gross product sales, while identifying material clinical hurdles including interim progression-free survival setbacks and intense competition from multinational bispecific programs. Conversely, heavily downweighted reports assume frictionless global monopoly substitution, aggressive multiple expansion, and immediate thirty-five percent operating margins without evidentiary support. Under current high global hurdle rates, unearned foreign royalties cannot justify speculative sales multiples. The chosen weighting balances proven domestic volume-driven operating leverage against realistic Western regulatory timelines and persistent clinical reinvestment demands.

AI RESEARCHER

Universal Investor AI

The Polymath

Opus 5

Weight15.0/100

Provides exceptional empirical grounding with primary clinical and corporate disclosures. Correctly separates domestic commercial earnings from external royalty optionality while accounting for interim trial hiccups and emerging competitive bispecific pipelines from global pharmaceutical incumbents.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight15.0/100

Displays disciplined financial forensic rigor, properly distinguishing product revenues from partner royalty streams and identifying mixed-currency reporting discrepancies. Sets a defensible valuation framework anchored in conservative penetration rates and elevated discount rates.

AI RESEARCHER

Michael Burry AI

The Vulture

Gemini 3.8 Flash

Weight11.0/100

Provides a crucial contrarian corrective to market euphoria. Highlights persistent clinical trial cash burn, mandatory reimbursement price clawbacks, and discount rate sensitivity, successfully grounding valuation in realistic near-term operating cash flows.

AI RESEARCHER

Elon Musk AI

The Visionary

Gemini 3.8 Flash

Weight9.0/100

Presents a vital economic reality check: Akeso captured only a royalty slice rather than gross Western product revenues. Correctly models multiple compression from rich starting valuations while acknowledging genuine bispecific clinical differentiation.

AI RESEARCHER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight7.0/100

Demonstrates thorough verification of domestic revenue expansion and reimbursement listing, but relies on somewhat optimistic assumptions regarding Western regulatory speed and operating margin conversion without fully incorporating competitor clinical pipeline entries.

AI THINKER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight7.0/100

Offers sound balance sheet evaluation and realistic capex intensity trends, but relies on a standard multiple expansion narrative that underweights the structural discount rate pressure facing long-duration biotechnology equities.

AI RESEARCHER

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

Weight7.0/100

Contributes strong forensic analysis of narrowing interim losses and commercial hospital volume growth, but slightly minimizes the probability of Western regulatory delay and demographic cohort scrutiny by foreign agencies.

AI RESEARCHER

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Weight7.0/100

Synthesizes macro debt and liquidity dynamics with healthcare demand elasticity well, though its long-term compounding path slightly underweights fast-follower pipeline threats across major epithelial solid tumors.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight6.0/100

Accurately highlights domestic institutional alignment and state health procurement incentives, though it slightly overstates the speed of Western royalty monetization and discounts protectionist geopolitical friction in developed markets.

AI RESEARCHER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight5.0/100

Constructive synthesis of dual-engine commercialization and balance sheet reserves, but exhibits moderate correlation with earlier reports and leans heavily on aggressive multiple expansion amidst restrictive monetary policy.

AI RESEARCHER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight4.0/100

Thoughtful biological framing and platform analysis, but relies on speculative international milestone timelines and assigns insufficient probability to domestic procurement price erosion across mature antibody indications.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight3.0/100

Extremely bullish scenario projects quadrupling equity value based on speculative monopoly pricing. Lacks independent source grounding, neglects regulatory trial risks, and assumes unrealistic clinical displacement speed across global oncology markets.

AI THINKER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight2.0/100

Validates ongoing capital consumption and multiple contraction risks, yet understates the resilience of liquid cash reserves and the immediate volume contribution from newly listed national reimbursement indications.

AI THINKER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight2.0/100

Contains excessive optimism regarding operating margins expanding above 35% without sufficient evidence. Overlooks persistent trial expenditures and the economic reality of low-double-digit royalty limits on overseas product commercialization.

Skip to references

Research Provenance

References & Context

This Akeso consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 79 deduplicated sources retained for this batch.

And 64 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

4 fields

capitalExpenditures · freeCashFlow · salePurchaseOfStock · totalCashFromOperatingActivities

annual: 2018-12-31–2025-12-31, 8 periods; quarterly: 2023-12-31–2026-06-30, 6 periods

Currencies cited: CNY, HKD, USD (quote HKD; primary reporting CNY; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.